We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding Oxford Biomedica Plc (OXB) this week highlighted varying sentiments regarding the company's stock prospects and potential takeover interest. A participant expressed skepticism about a £7-9 bid being adequate, while another reported selling shares, suggesting fluctuating trading dynamics. Notably, discussions revealed apprehensions regarding OXB's defenses against opportunistic bids, with sentiments emerging that the company's current share price may suggest vulnerability. This concern was echoed when one investor observed, “I have to say that the impression I took from the AGM was that there was a feeling of potential vulnerability to an opportunistic bid.”
In terms of financial outlook, speculation on OXB’s revenues for the upcoming year indicated a prediction of approximately £180 million, pointing towards a year of record revenue. Quotes such as "the behavior of the company hasn't appeared to be helping their share price" encapsulated the frustration of investors amid perceived underperformance and challenges in the market context. Despite these concerns, discussions about the company's strategic position and future prospects remained active, with hopes for a more stable and significantly valued future. Several participants highlighted the potential impact of OXB's reintegration into indices like the FT250 as a catalyst for renewed investor interest. Overall, while some investors remain hopeful about OXB's future growth, underlying worries continue to cloud investor sentiment regarding its valuation and the competitive pharmaceutical market.
Show more
Oxford Biomedica Plc (LSE: OXB) has reported several key developments in recent weeks, highlighting its ongoing strategic initiatives and governance changes. Notably, as of December 2, 2024, the company's total issued share capital stands at 105,938,933 ordinary shares, which shareholders can use for determining notification obligations under the FCA's Disclosure Guidance. Additionally, new executive compensation arrangements were announced, including the grant of long-term incentive plan (LTIP) awards to key management, scaled back by 20% as part of best practice governance.
The company is also expanding its engagement in the biopharmaceutical community, with a forthcoming free webinar scheduled for December 9, 2024, focused on the use of advanced robotics in accelerating the development of viral vector products. This reflects OXB's commitment to innovation in cell and gene therapy manufacturing. Furthermore, the Board has undergone changes with the appointment of Colin Bond as a new Non-Executive Director, effective January 1, 2025, as part of planned succession efforts. These developments demonstrate OXB's proactive approach to governance and its focus on enhancing operational capabilities within the competitive biopharmaceutical landscape.
Show more
Just been watching the cinema film about Trump's early days..quite some life he has led. |
Worth keeping an eye on Milei/Argentina. It may be the start of something broader, particularly if Musk, sorry, Trump, gets in. |
We’re all singing from pretty much the same song sheet here. |
How many "workers" in the UK receive a cheque each month or if they have an emergency write out a cheque? Not many I suggest. |
I hate my phone keyboard |
March, notatch. |
Read the thread to get an idea. You'll need to go back to Match to get the full story. |
is this a good share |
FT250 inclusion now feels like a probability rather than a possibility. |
So the auction trade to end there was both 12 month highest intraday and closing price and on good volume. |
Apparently you need to be paid by cheque once a month to be a working person. |
Without going into politics, it appears Sir Starmer's very prestigious previous life is now causing problems in his current role as Prime Minister. |
“Speaking to broadcasters in Samoa, Keir Starmer said he would not use the term-‘working people’-for people who had income from assets such as shares or property. “They wouldn’t come within my definition,” he said. Downing Street hastily clarified that the prime minister did not mean people who owned small amounts of, for example, stocks or shares.” |
Unknown unknowns Dom. |
More effort needed to promote Boston part? Big pharma 'feel safer' buying in the good ole US of A. |
Reading my newsfeed this morning I was distracted by this:- |
Back to OXB and earlier in the year we were all curious about why Frank had become chairman of ArcticZymes and if there was something brewing there. |
Yes i agree with all that Harry.It seems inevitable that Labour will repeat some,if not many,of the mistakes witnessed in the 70s.The road to economic ruin is invariably littered with apparently good socialist intentions.Thereagai |
It's very hard to compare SJ, as until quite recently the US basically had 2 conservative parties. I'm sure you know but early days Ronald Reagan was a card carrying democrat and when asked why he changed, he replied that he hadn't changed it was the democrats who had. Go back even further and the republicans are the abolitionists and hold power in what are now the democratic strongholds of the north east. |
It's far from certain that the US election result will be a smooth uncontested affair and there could well be 10 days of uncertainty hanging over markets following bonfire night on 5th November.The polls are nudging in Trump's favour and discussions i've had with American tourists in various European localities over the last year have on balance pointed in that direction.Kamala Harris's policies are pretty radical.For example,she suggests reforming capital gains tax to be taxed as income,some of her policies are right out of the muted Rachel Reeves handbook.(What a farce waiting for this UK budget has become).I'm not surprised Labour party members are hanging round Democratic conventions,they could be bedfellows. |
Or one of them maybe? (we have 4 in P3). |
Harry, good find. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions